Harnessing immune responses in the tumor microenvironment: all signals needed.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 24097857.
- Also identified by DOI 10.1158/1078-0432.CCR-13-2424 and PMC identifier 3839670.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
An agonist CD40 monoclonal antibody (CP-870,893), in combination with gemcitabine, is well tolerated in patients with advanced pancreatic adenocarcinoma. The combination results in induction of cytokines, B cell activation, and clinical responses. These findings support testing of immunotherapies in combination with other established and targeted therapies.
Medical subject headings
- Antibodies, Monoclonal
- CD40 Antigens
- Carcinoma, Pancreatic Ductal
- Pancreatic Neoplasms